<DOC>
	<DOCNO>NCT01996319</DOCNO>
	<brief_summary>This study design assess effect QVA149 ( 110/50 ug q.d . ) versus placebo pulmonary function average physical activity level patient moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Randomized , Double-blind , Placebo-controlled , Multicenter , Cross-over Study Assess Effects 3 Week Therapy Each With QVA149 Versus Placebo Pulmonary Function Average Physical Activity Levels Patients With COPD .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Patients stable COPD accord current GOLD guideline ( GOLD 2013 ) . Current exsmokers smoke history least 10 pack year ( e.g . 10 pack year = 1 pack /day x 10 yr , ½ pack/day x 20 yr ) .. Patients airflow limitation indicate postbronchodilator FEV1 ≥40 % &lt; 80 % predict normal , postbronchodilator FEV1/FVC &lt; 0.70 Patients condition contraindicate treatment , history reactions/hypersensitivity follow inhaled drug , drug similar class component thereof , anticholinergic , long short act beta2 agonist , sympathomimetic amine , lactose excipients Patients clinically significant ECG abnormality Visit 1 , judgment investigator would potential risk enrol study . Patients paroxysmal ( e.g . intermittent ) atrial fibrillation exclude . Patients persistent atrial fibrillation define continuous atrial fibrillation least 6 month control rate control strategy ( i.e. , beta blocker , calcium channel blocker , pacemaker placement , digoxin ablation therapy ) least 6 month may consider inclusion . In patient , atrial fibrillation must present baseline screen visit , rest ventricular rate &lt; 100/min . Patients Type I uncontrolled Type II diabetes patient history blood glucose level consistently outside normal range Patients narrowangle glaucoma , symptomatic prostatic hyperplasia bladderneck obstruction moderate severe renal impairment urinary retention . Patients history malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . Patients nonmelanoma skin carcinoma may consider study . Patients body mass index ( BMI ) 40 kg/m2 . Women pregnant breast feeding Patients require long term oxygen therapy daily basis chronic hypoxemia . Patients COPD exacerbation require treatment antibiotic and/or oral corticosteroid and/or hospitalization 6 week prior screen . Patients respiratory tract infection within 4 week prior screen . Patients history asthma . Patients concomitant pulmonary disease Patients clinically significant bronchiectasis . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
</DOC>